



LB Pharmaceuticals, Inc. Announces the Publication of Its First Peer-Reviewed Manuscript

Publication in the journal ACS Omega Describes the Polypharmacy of LB-102

New York, NY (August 15th, 2019) – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced that a new peer-reviewed manuscript entitled “Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7” has been published in the journal ACS Omega Vol 4 pages 141151-141154 and is available online both at pubs.acs.org/acsomega and LB’s Corporate website.

Amisulpride was developed by Sanofi-Aventis in the 1990s and is in wide use throughout Europe and the Pacific Rim for the treatment of schizophrenia. Amisulpride is dosed as a racemate although the major efficacy driver is assumed to be mediated through the S enantiomer’s binding to D2 receptors. Prior reports suggest amisulpride’s efficacy against the negative symptoms of schizophrenia is mediated through 5HT7 receptor binding.

The Company’s business model looks to develop successful ex-US therapeutics for the US market. While developing a successor to amisulpride, LB needed to address the binding specificity of the 5HT7 receptor. Should the 5HT7 receptor prefer the S enantiomer, then, chirally pure LB-103 would be put forward for clinical development. On the other hand, should the 5HT7 receptor prefer the R enantiomer, racemic LB-102 would advance to the clinic. In the ACS Omega report, by use of receptor binding studies, LB discovered that the R enantiomer has an almost 50-fold preference for the 5-HT7 receptor. Thus, to capture efficacy in the cognitive effects of schizophrenia, racemic LB102 was selected for clinical study. The report in ACS Omega contains the rational, study design and findings for moving the racemate LB-102 into clinical development.

About LB Pharmaceuticals

LB is a development stage CNS-focused life science company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed, in the United States. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs.

Contact

Zachary Prensky, President & CEO
Zach@LBPharma.us (212) 605-0230
575 Madison Avenue, 10th Floor NY NY 10022